Post COVID-19 invasive mucormycosis and actinomycosis co-infection: a case report

Authors

  • Neha Mishra Department of Infectious Diseases, Manipal Hospitals, Bangalore, Karnataka, India
  • Venkata Sai Shashank Mutya Department of General Medicine, Manipal Hospitals, Bangalore, Karnataka, India
  • Irfan Ibrahim K. Department of General Medicine, Manipal Hospitals, Bangalore, Karnataka, India
  • Girish Rai Department of Otorhinolaryngology, Manipal Hospitals, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/issn.2454-5929.ijohns20213189

Keywords:

COVID-19, Mucormycosis, Actinomycosis, Immunosuppression, Functional endoscopic sinus surgery

Abstract

Actinomyces are commensals of human oropharynx and actinomycosis is considered mainly as an endogenous infection that is triggered by a mucosal lesion. Typically, the disease presents as a slowly progressive painless indurated mass evolving into multiple abscesses with draining sinus tracts sometimes expressing a typical yellow exudate with characteristic sulfur granules. The gold standard of diagnosis is histological examination and bacterial culture of the tissue. Most isolates are susceptible to beta lactams and they are the treatment of choice along with surgical management with drainage of abscesses and excision of recalcitrant fibrotic lesions and debridement of necrotic bone tissue. Here we present a case of 37-year-old male patient who has developed severe COVID-19 infection following which he developed invasive mucormycosis followed by actinomycosis. We postulate that the lymphopenia and the use of immunosuppressants used in treatment of COVID-19 lead to mucormycosis and aggressive debridement used as a strategy in treatment of mucormycosis led to colonization of actinomyces leading to cervicofacial actinomycosis.

References

Wong VK, Weston VC. Actinomycosis. BMJ. 2011;343:6099.

Valour F, Senechal A, Dupleux C. Actinomycosis: Etiology, clinical features, diagnosis, treatment and management. Infect Drug Resist 2014;7:183-97.

Pulverer G, Schutt- Gerowitt H, Schaal KP. Human cervicofacial actinomycoses: microbiological data for 1997 cases. Clin Infect Dis. 2003;37(4):490-97.

Oostman O, Smego RA. Cervicofacial actinomycosis diagnosis and management. Curr Infect Dis Rep. 2005;7(3):170-74.

Wiersinga WJ, Rhodes A, Cheng AC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)-A Review. JAMA. 2020;12839:E1-13.

Song G, Liang G, Liu W. Fungal co-infections Associated with Global COVID-19 Pandemic: A Clinical and diagnostic perspective from China. Mycopathologia. 2020;185:599-26.

Spelberg B, Edwards J. Novel perspectives on Mucormycosis: Pathophysiology, Presentation and Management. Clin Microbiological Reviews. 2005;556-69.

Downloads

Published

2021-08-23

Issue

Section

Case Reports